Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Sequencing › Ovarian Cancer Mutational Signatures, Immune Features Tied to Combination Treatment Response

Ovarian Cancer Mutational Signatures, Immune Features Tied to Combination Treatment Response

Mar 19, 2020
|
staff reporter

NEW YORK – A new genomic, immune profiling, and imaging study suggests there may multiple signatures for predicting response to a PARP inhibitor and checkpoint immunotherapy drug combination in advanced ovarian cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
27
Featured Webinar

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. 

What's Popular?

In Sequencing

  1. Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.